Burroughs Wellcome Co.

Glaxo Wellcome Inc.

Krenitsky Pharmaceuticals, Inc.

Remedi, Inc.

Thomas A Krenitsky

George Walter Koszalka

Janet L Rideout

Lilia M Beauchamp

Joel Van Tuttle

Charlene L Burns

Susan Mary Daluge

James L Kelley

Devron R Averett

Saad George Rahim

Gertrude B Elion

Gerald Wolberg

John W Selway

David J Porter

Stanley Robert Bushby

Martin J Slater

Lowrie M Beacham, Iii

Frank Leslie Boyd, Jr

Sylvia M Tisdale

Wayne H Miller

Tom Spector

Jeremy Ford

Disclosed are methods of treating a subject having a disease or disorder by administering a monoamine oxidase inhibitor in combination with a serotonin receptor agonist, which in some embodiments is a deuterated serotonin receptor agonist. In some aspects, the disclosure further relates to pharmaceutical compositions and kits comprising a monoamine oxidase inhibitor and a serotonin receptor agonist. In some embodiments, the monoamine oxidase inhibitor is a MAO-A-selective inhibitor such as CX157, and the serotonin receptor agonist is a serotonin 2A receptor agonist such as N,N-dimethyltryptamine (DMT), or deuterated DMT.

Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use

The present invention relates to a series of novel substituted 5-alkynyl pyrimidines, pharmaceutical compositions which contain them, methods for their preparation, and their use in therapy, particularly in the treatment of neurodegenerative or other neurological disorders of the central and peripheral nervous systems, including age related cognitive disorders such as senility and Alzheimer's disease, nerve injuries, peripheral neuropathies, and seizure disorders such as epilepsy.

Substituted 5-alkynyl pyrimidines having neurotrophic activity

The present invention relates to a series of substituted pyrimidines, to pharmaceutical compositions which contain them, to methods for their preparation and to their use in therapy, particularly in the treatment of neurodegenerative or other neurological disorders of the central and peripheral nervous systems.

Neurotrophic substituted pyrimidines

The present invention relates to novel derivatives of a series of substituted pyrimidines, to pharmaceutical compositions which contain them, to methods for their preparation and to their use in therapy, particularly in the treatment of neurodegenerative or other neurological disorders of the central and peripheral systems.

Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system

5-Fluorouracil derivatives

6-Alkoxy derivatives of Ara-G, and pharmaceutically acceptable esters thereof, are described as being useful in tumor therapy. Novel pharmaceutically acceptable esters, their preparation and pharmaceutical formulations containing them are also disclosed.

Tumor treatment with arabinofuranosyl purine derivatives

6-Alkoxy derivatives of Ara-G, and pharmaceutically acceptable esters thereof, are described as being useful in tumour therapy. Novel pharmaceutically acceptable esters, their preparation and pharmaceutical formulations containing them are also disclosed.

Therapeutic methods for using ARA-G derivatives

2',3'-dideoxy-3'-fluoro-purine ribonucleosides

Therapeutic nucleosides

A method for treating HIV infections comprising administering a composition whose active ingredient is 2',3'-dideoxy-3'-fluoro-5'-chlorouridine.

Method of treating HIV infections with

The present invention relates to certain 2',3'-dideoxynucleosides and pharmaceutically acceptable derivatives thereof, methods for preparing them, their use in the treatment and prophylaxis of viral, especially retroviral, infections, and pharmaceutical formulations containing them.

Methods of treating hepatitis B virus infection with therapeutic

The 5'-O-proprionyl and 5'-O-butyryl esters of 2-amino-6-methoxy-9-(B-D-arabinofuranosyl)-9H-purine useful as inhibitors of varicella zoster virus.

5'-O-propionyl and 5'-O-butyryl esters of

Method for treating T-cell lymphoblastic leukemia with ara-G nucleoside

The compound 9-B-D-arabinofuranosyl-2-amino-6-methoxy-9H-purine along with its 5'-acetyl and 5'-(4-methoxy-4-oxobutyryl derivatives are disclosed as inhibitors of Varicella Zoster virus (VZV).

9-.beta.-D-arabinofuranasyl-2-amino-6-methaoxy-9H-purine

Growing community of inventors

Chapel Hill, NC, United States of America

Thomas A Krenitsky